The biological basis for interleukin-2 anticancer therapy.
Silver
H K
HK
Department of Advanced Therapeutics, Cancer Control Agency of British Columbia, Vancouver, Canada.
Klasa
R J
RJ
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004195:Disease Models, Animal; D004347:Drug Interactions; D007376:Interleukin-2 / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology; D008213:Lymphocyte Activation / Q000502:physiology; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D009374:Neoplasms, Experimental / Q000628:therapy*; D015375:Receptors, Interleukin-2 / Q000378:metabolism
D007376:Interleukin-2; D015375:Receptors, Interleukin-2